Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by icecubeon Sep 30, 2015 3:14pm

51 Views

Post# 24150316

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Caution

To quote smush74, "There was and is no fraud PERIOD".

Quit blubbering.

All of the information was available when the stock was over $10 per share.

Take responsibility for your own actions, or inaction, accept the results and quit blaming others for your mistakes.

TheElephantisin wrote:
What do you call giving each employee a million dollar a year salary, + stock options while they drive up 40 million dollars of debt at 10% interests?

Bullboard Posts

Opawica seeks drill permits for Bazooka Gold Targets in Abitibi